More than 20 billion dollars worth of biopharmaceuticals are scheduled to go off-patent by 2006. Given the strong political impetus and the development of technological tools that can answer the questions regulatory authorities may raise, it is inevitable that the FDA and EMEA will allow biogeneric or biosimilar products. Even with all the regulato
Köp den här e-boken och få 1 till GRATIS!
Språk Engelska ● Formatera PDF ● Sidor 584 ● ISBN 9781420037937 ● Utgivare CRC Press ● Publicerad 2002 ● Nedladdningsbara 3 gånger ● Valuta EUR ● ID 5697838 ● Kopieringsskydd Adobe DRM
Kräver en DRM-kapabel e-läsare